Philipp Erben Selected Research

galactosylceramide sulfotransferase

1/2021

The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philipp Erben Research Topics

Disease

30	Neoplasms (Cancer) 01/2022 - 12/2008
23	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 10/2016
17	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2014 - 01/2007
16	Carcinoma (Carcinomatosis) 01/2022 - 01/2012
15	Non-Muscle Invasive Bladder Neoplasms 01/2022 - 11/2016
7	Rectal Neoplasms (Rectal Cancer) 01/2016 - 12/2008
6	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 01/2017
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2016 - 07/2012
5	Eosinophilia 05/2014 - 06/2007
3	Breast Neoplasms (Breast Cancer) 05/2021 - 07/2017
3	Neoplasm Metastasis (Metastasis) 01/2019 - 08/2014
3	Hypereosinophilic Syndrome (Loeffler Endocarditis) 12/2013 - 12/2008
3	Pdgfra-Associated Chronic Eosinophilic Leukemia 12/2013 - 10/2006
3	Squamous Cell Carcinoma of Head and Neck 05/2013 - 04/2011
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2011 - 05/2008
3	Leukemia 03/2011 - 05/2008
2	Lymphatic Metastasis 01/2021 - 12/2018
2	Colorectal Neoplasms (Colorectal Cancer) 11/2011 - 12/2008
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2011 - 10/2006
2	Philadelphia Chromosome 08/2010 - 06/2007
2	Blast Crisis (Blast Phase) 08/2010 - 04/2007
2	Disease Progression 09/2009 - 01/2007
2	Diarrhea 08/2009 - 07/2009
2	Chromosome Aberrations (Chromosome Abnormalities) 02/2009 - 06/2007
2	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2007 - 10/2006
1	Inflammation (Inflammations) 04/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2021
1	Pancreatitis 01/2021
1	Hyperplasia 06/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019
1	Adenocarcinoma 01/2019
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2019

Drug/Important Bio-Agent (IBA)

26	Imatinib Mesylate (Gleevec)FDA Link 09/2014 - 10/2006
23	Messenger RNA (mRNA)IBA 01/2022 - 10/2006
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2008
10	ParaffinIBA 01/2021 - 01/2016
8	Formaldehyde (Formol)FDA Link 01/2021 - 11/2016
7	RNA (Ribonucleic Acid)IBA 04/2021 - 01/2008
7	Tyrosine Kinase InhibitorsIBA 12/2013 - 01/2007
7	Dasatinib (BMS 354825)FDA Link 10/2013 - 04/2007
6	Phenobarbital (Luminal)FDA Link 01/2021 - 03/2017
6	Phosphotransferases (Kinase)IBA 01/2016 - 01/2007
4	Pharmaceutical PreparationsIBA 01/2022 - 05/2013
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2016
4	ErbB Receptors (EGF Receptor)IBA 01/2018 - 11/2011
4	Capecitabine (Xeloda)FDA Link 01/2016 - 12/2008
4	nilotinib FDA Link 12/2013 - 05/2008
4	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 05/2013 - 10/2006
3	Androgen Receptors (Androgen Receptor)IBA 06/2021 - 06/2017
3	Biological ProductsIBA 01/2021 - 09/2014
3	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2004
3	PlatinumIBA 01/2020 - 05/2013
3	CateninsIBA 04/2016 - 12/2014
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2014 - 08/2011
3	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 05/2014 - 02/2009
3	Cetuximab (Erbitux)FDA Link 11/2011 - 12/2008
3	Irinotecan (Camptosar)FDA LinkGeneric 08/2009 - 12/2008
2	Hormones (Hormone)IBA 04/2022 - 09/2017
2	Docetaxel (Taxotere)FDA Link 04/2022 - 05/2013
2	human ERBB2 proteinIBA 05/2021 - 01/2018
2	Cisplatin (Platino)FDA LinkGeneric 04/2021 - 01/2018
2	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 01/2021 - 01/2018
2	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2021 - 01/2018
2	Long Noncoding RNAIBA 12/2020 - 11/2020
2	B7-H1 AntigenIBA 01/2020 - 01/2019
2	Hematoxylin (Haematoxylon)IBA 01/2019 - 08/2014
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2019 - 08/2014
2	tyrosine receptor (receptor, tyrosine)IBA 01/2016 - 04/2011
2	Carboplatin (JM8)FDA LinkGeneric 07/2012 - 04/2011
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2012 - 05/2010
2	bcr-abl Fusion ProteinsIBA 04/2011 - 02/2008
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2022
1	Estrogen Receptor alphaIBA 01/2022
1	cyclopropapyrroloindoleIBA 11/2021
1	Estrogen ReceptorsIBA 05/2021
1	Adenosine Monophosphate (AMP)IBA 01/2021
1	Interleukin-22 (IL-22)IBA 01/2021
1	Neuropilin-2IBA 01/2021
1	galactosylceramide sulfotransferaseIBA 01/2021
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 06/2020
1	Programmed Cell Death 1 ReceptorIBA 01/2020
1	Nucleic AcidsIBA 12/2019
1	Microfilament Proteins (Actin Binding Proteins)IBA 11/2019
1	SteroidsIBA 02/2019
1	atezolizumabIBA 01/2019

Therapy/Procedure

25	Therapeutics 04/2022 - 10/2006
15	Cystectomy 01/2022 - 10/2016
8	Drug Therapy (Chemotherapy) 04/2022 - 05/2013
4	Immunotherapy 01/2022 - 01/2018
4	Neoadjuvant Therapy 05/2021 - 07/2009
4	Chemoradiotherapy 01/2016 - 12/2008
2	Castration 01/2018 - 03/2017
1	Prostatectomy (Retropubic Prostatectomy) 06/2020
1	Adjuvant Chemotherapy 01/2020
1	Aftercare (After-Treatment) 01/2020
1	Intravesical Administration 01/2019